The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Eli Lilly, the manufacturer of the drug Zyprexa, may face more legal troubles after the FDA told the company it would delay the approval of its new drug Symbyax for hard-to-treat depression because the agency wanted more information about the risk of diabetes in the medicine’s prescribing label. Symbyax combines Lilly’s antipsychotic pill Zyprexa and the antidepressant Prozac. Zyprexa has already been shown to cause diabetes and pancreatitis. The company has come under heavy criticism for failing to disclose dangerous and often fatal side effects such as
fever, stiff muscles, confusion, sweating, fast or irregular heartbeats, spasmodic muscular movements, sudden headaches, problems with vision, speech or balance, hallucinations, and increased thirst and frequent urination.

For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest